CDMRP Neurofibromatosis Research
The U.S. Department of Defense Seeks Innovative Clinical Trials
CDMRP Funding Opportunity for Neurofibromatosis Research: Accelerating New Treatments (Up to $1.6 Million)
The U.S. Department of Defense Seeks Innovative Clinical Trials
The Department of Defense (DoD), through the Congressionally Directed Medical Research Programs (CDMRP) Neurofibromatosis Research Program (NFRP), is offering a substantial grant to support clinical trials for Neurofibromatosis (NF).
What is Neurofibromatosis?
NF is a genetic disorder that causes tumors to grow on nerves throughout the body. There is currently no cure for NF, but clinical trials are essential for developing new treatments and improving patient outcomes.
About the Grant
- Program: CDMRP Neurofibromatosis Clinical Trial Award
- Funding: Up to $1.6 million will be awarded to a single application.
- Goal: To rapidly implement clinical trials with the potential to significantly improve treatment or management of NF.
Who can apply?
- Any type of organization can apply, including universities, hospitals, research institutions, and private companies.
- Collaborations between researchers from academia, industry, the military, and government agencies are highly encouraged.
Types of Trials Supported:
- The grant program supports a wide range of clinical trials, from small early-stage trials to large-scale studies.
- Examples include:
- Pilot trials to test the safety and feasibility of new drugs or therapies.
- Phase II trials to evaluate the effectiveness of promising treatments.
- Large-scale Phase III trials to confirm the efficacy of new treatments in a broader patient population.
What the Grant Covers:
- The grant will cover the costs associated with conducting the clinical trial, such as personnel, supplies, and data analysis.
How to Apply:
- The application deadline is October 3, 2024. Don’t miss out!
- Contact: CDMRP Help Desk (301-682-5507 or help@eBRAP.org)
This is an official U.S. government website.
Up to $1.6 Million to Fight Neurofibromatosis: New Clinical Trial Grant from DoD
The U.S. Department of Defense Calls for Innovative Research Proposals
The Department of Defense (DoD), through its Congressionally Directed Medical Research Programs (CDMRP) Neurofibromatosis Research Program (NFRP), is offering a significant grant opportunity to accelerate progress in treating Neurofibromatosis (NF).
What is Neurofibromatosis?
NF is a genetic disorder that causes tumors to develop on nerves throughout the body. These tumors can cause pain, disfigurement, and other health problems. While there is currently no cure for NF, clinical trials are crucial for developing new treatments and improving the lives of patients.
About the CDMRP Neurofibromatosis Clinical Trial Award
- Grant amount: Up to $1.6 million will be awarded to a single, exceptional application.
- Program Goal: To rapidly implement clinical trials with the potential to make a significant impact on treating or managing NF.
Who can apply?
The program welcomes applications from a wide range of organizations:
- Universities and academic institutions
- Hospitals and research centers
- Non-profit organizations
- Private companies
The CDMRP particularly encourages collaborative efforts between researchers from various backgrounds, including:
- Academia
- Industry (pharmaceutical companies, biotechnology firms)
- Military treatment facilities (e.g., Walter Reed National Military Medical Center)
- Veterans Affairs (VA) hospitals
- Other government agencies
These collaborations can leverage expertise, resources, and access to unique patient populations, ultimately accelerating progress in NF research.
Types of Clinical Trials Supported
The program supports a variety of clinical trials at different stages of development:
- Early-stage (Phase 0 and I): Small, pilot studies to assess the safety and feasibility of new drugs, therapies, or devices for treating NF.
- Mid-stage (Phase II): Trials designed to evaluate the effectiveness of promising treatments in a small group of patients with NF.
- Large-scale (Phase III): Comprehensive studies to confirm the efficacy and safety of a new treatment in a broader patient population.
What the Grant Covers
The CDMRP Neurofibromatosis Clinical Trial Award will provide funding for various costs associated with conducting the clinical trial, such as:
- Salaries for research personnel
- Costs of medications and other supplies
- Data collection and analysis
- Patient recruitment and retention activities
How to Apply and Important Dates
- The application deadline is October 3, 2024. Act fast to secure this critical funding!
- Contact for inquiries: CDMRP Help Desk (301-682-5507 or help@eBRAP.org)
This is an official U.S. government website.
Additional Considerations:
- You may want to mention specific types of NF (NF1, NF2, Schwannomatosis) the program is interested in.
- Briefly explain the significance of military and veteran inclusion in NF research (e.g., higher rates of certain health conditions in veterans).
